Atlas Trials

A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer

Clinical trial NCT07455019 · RECRUITING

Trial details

NCT number
NCT07455019
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Esophageal Cancer
Start date
2025-05-01
Primary completion
2028-04-30
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.